Introduction {#Sec1}
============

The completion of the Human Genome Project marked a new era in our understanding of molecular genomics \[[@CR1], [@CR2]\]. With this remarkable feat, previously unknown and uncharacterized proteins were revealed. The initial hope was that perhaps hidden within the vastness of the human genome were "truly novel proteins" with concomitant novel functions in biology. A "truly novel protein" is defined as one which has no known counterparts---that is, not just a newly-found member of a known protein family, but a novel protein that defines a new protein class or family \[[@CR3]\]. The process of identifying and characterizing novel proteins defining a new protein class further opens up the possibility of discovering novel biological functions and pathways. This unveiling, in turn, could lead to significant progress in the treatment of human disease by defining new therapeutics and novel molecular targets.

In this paper, we provide the initial physical and functional characterization of a novel protein that defines a new protein class, designated as HSS1 (*H*ematopoietic *S*ignal peptide-containing *S*ecreted *1*). HSS1 and its membrane-bound splice variant, HSM1 (*H*ematopoietic *S*ignal peptide-containing *M*embrane domain-containing *1*), form the first members of a novel protein class or family in that these proteins have no homology to any known proteins or any known protein domains. Given the novelty of HSS1, the elucidation of its function may provide insights into previously unknown biological functions.

The discovery of HSS1 started with a search for novel secreted proteins differentially expressed in hematopoietic stem cells (HSCs), implying a possible role in stem cell biology. We analyzed the gene expression profiles of three highly purified populations of murine HSCs \[[@CR4]\]. This analysis led to the discovery of both mouse and human homologs of HSS1. But since HSS1 is a novel gene/protein that defines a novel protein class, no structural clues to its function were available. The only apparent functional clue was the gene *locus* of HSS1. Interestingly the gene related to human HSS1 (*h*HSS1) maps to 19q13.33, a genomic site of putative but largely uncharacterized suppressor(s) of glioma and other cancers \[[@CR5], [@CR6]\]. This observation led us to investigate a possible role for *h*HSS1 in glioma malignancy. Thus, in this study we report the identification and characterization of a novel protein defining a new protein class, HSS1, as well as provide insight regarding its functional role in glioma tumor biology.

Materials and methods {#Sec2}
=====================

Isolation of HSS1 cDNA {#Sec3}
----------------------

The murine form of HSS1 (*m*HSS1) was isolated via PCR from a lineage-negative mouse bone marrow cDNA library \[[@CR7]\]. The human form of HSS1 (*h*HSS1) was isolated from a cDNA human testis library (Human MTC Multiple Tissue cDNA Panel II, Clontech). Primers were based upon predicted gene sequences and PCR products were sequenced to confirm the DNA sequence of both human and mouse HSS1 genes.

Cell culture and *h*HSS1 expression vector construct {#Sec4}
----------------------------------------------------

Human embryonic kidney 293T and A172 glioma cell lines (ATCC, Manassas, VA, USA) were cultured in DMEM supplemented with 10% FBS. The human U87 glioma cell line (ATCC HTB-14) was maintained in alpha-MEM supplemented with 10% FBS, non-essential amino acids, sodium pyruvate and sodium bicarbonate. The pTT3-*h*HSS1 expression construct was kindly provided by Dr W. French Anderson. The *h*HSS1 cDNA was subcloned from pTT3 vector into the *Eco*RI and *Hin*dIII sites of pcDNA.3.1 mammalian expression vector (Invitrogen, Carlsbad, CA, USA). The construct had a 6-His tag in-frame fused at the C-terminal of *h*HSS1 gene. The resultant construct pCDNA3.1-*h*HSS1 was verified by sequencing analysis.

Transient transfection and immunoblotting {#Sec5}
-----------------------------------------

Supernatants containing the *h*HSS1 protein were produced by transient transfection of 293T cells harvested after 48 h post-transfection using the Calcium Phosphate Transfection kit (Invitrogen) and 4 μg of plasmid DNA purified with a Qiagen column (Qiagen, Valencia, CA, USA). Conditioned media from 293T cells were harvested, concentrated using a Macrosep centrifugal device (Pall, East Hills, NY, USA) and stored in aliquots at 4°C. Protein expression was confirmed by Western blot in both supernatant and cell lysate prepared from 2 × 10^5^ cells using a standard protocol and mass spectrometry. An anti-His (C-term)-HRP antibody (Invitrogen) allowed detection of *h*HSS1 protein by Western blot. Immunoreactive bands were visualized by colorimetric detection using TMB solution (Invitrogen). The glycosylation pattern of HSS1 was assessed by treating cell lysates with PNGase F, Sialidase and O-glycanase.

Detection of *h*HSS1-mRNA by reverse transcription (RT)-PCR {#Sec6}
-----------------------------------------------------------

Total RNA was isolated from A172 and U87 cell lines using the RNeasy minikit (Qiagen). The RT-PCR reaction was carried out by using SuperScrip III One-Step RT-PCR (Invitrogen) and 1 μg of total RNA. The primers specific for HSS1 were: 5′-TCCTGCTCTTGCTGATGG-3′ (forward); 5′-GAGACATAGCCACCAGCTTC-3′ (Reverse). The conditions of the reaction were those suggested by the manufacturer. A GAPDH mRNA control was also amplified by PCR according to the manufacturer. PCR products were then checked via agarose gel electrophoresis.

Selection of stable transfectants {#Sec7}
---------------------------------

The glioblastoma-derived A172 and U87 cell lines were transfected as mentioned above, either with pcDNA3.1-*h*HSS1 or with pcDNA3.1 empty vector. After 24 h, 800 μg ml^−1^ of G-418 (Invitrogen) was added to the culture. Stable selection was performed for 4-8 weeks and the stably transfected clones were then expanded and cryopreserved in aliquots for further use. The expression of *h*HSS1 mRNA was confirmed using RT-PCR.

Quantitative proliferation assay {#Sec8}
--------------------------------

Cell viability was measured by cell counting using trypan blue exclusion on wild-type (untransfected cells), on pcDNA3.1 empty vector and pcDNA3.1-*h*HSS1 clones. U87 cells (8 × 10^4^) were plated in triplicate in 10 cm plates and incubated at 37°C, 5% CO~2~. After 6 days, the number of cells was quantified and the values were expressed as means. Also, 5 × 10^3^ U87 cells were seeded in septuplicate in 96-well plates and after 3 days of incubation the number of cell aggregates formed was determined in the central field of each well. A172 cells (8 × 10^4^) were plated in triplicate in 10 cm plates and after 7 days the cells were harvested and counted. To test the plating efficiency of A172 cells, 2 × 10^3^ A172 cells were seeded in triplicate in 10-cm plates. After 23 days, cell colonies were stained for 1 h with 0.001% neutral red (Sigma-Aldrich, St. Louis, MO, USA) in PBS, after that, plates were photographed. At least two experiments using each assay were performed.

Growth inhibition of cells {#Sec9}
--------------------------

U87 and A172 wild-type cells, pcDNA3.1 and pcDNA-*h*HSS1 cells were seeded at a density of 9 × 10^4^/2 ml medium in 6-well plates in triplicate. Over the course of 8 days, cells were harvested and counted by trypan blue dye exclusion.

qRT-PCR {#Sec10}
-------

For the analysis of *h*HSS1 expression in brain cancer tissue we used the TissueScan Brain Cancer Tissue qPCR Array I---HBRT102 (Origene Technologies, Rockville, MD), consisting of 48 human brain tissues normalized against β-actin gene. This array included meningiomas, oligodendroglioma and astrocytomas. Normal brain tissue was also evaluated using Human Brain Tissue qPCR Panel I---HBRT101 (Origene Technologies), consisting of 24 human brain tissues normalized against GAPDH gene. qRT-PCR was performed using SYBR Green PCR master mix (Roche Diagnostics, Indianapolis, IN) using primers specific for *h*HSS1 (forward 5′-CAGCAGGATGGTACCTTGTC-3′ and reverse 5′-GAGACATAGCCACCAGCTTC-3′). Relative mRNA levels of *h*HSS1 were calculated using the LightCycler 480 Relative Quantification Software 1.2 (Roche Diagnostics).

Immunocytochemical and immunohistochemical analysis {#Sec11}
---------------------------------------------------

*h*HSS1 was detected in U87 and A172 cells stably expressing *h*HSS1 and in formalin-fixed paraffin-embedded tissue sections of glioma tumors. U87 and A172 cells (4 × 10^4^ cells) were cultured overnight in 4-well chamber slides coated with 5 μg/ml fibronectin. Cultures were fixed in cold methanol for 10 min at −20°C. Tissue sections from four low-grade diffuse astrocytomas (WHO grade II) and four high-grade astrocytomas (glioblastoma multiform, WHO grade IV) were incubated in AquaDepar (Biocare Medical, Concord, CA) reagent at 70°C for 10 min. After deparaffinization, antigen retrieving was performed by using Reveal reagent (Biocare Medical). To block non-specific protein staining, cultures and sections were incubated in background sniper (Biocare Medical) for 10 min. *h*HSS1 was detected by incubation for 2 h with a custom made rabbit polyclonal anti-*h*HSS1 serum raised against synthetic peptide corresponding to amino acids 108--123 using 1:250 and 1:40 dilution for cultures and tissue sections, respectively (Genescript, Piscataway, NJ). This step was followed by incubation for 1 h at RT inImmPRESS reagent anti-rabbit Ig Peroxidase (Vector Laboratories, Burlingame, CA) and 30 min incubation in ImmPact AEC Peroxidase Substrate (Vector Laboratories). Slides were further counterstained with hematoxylin. Negative control included a stain containing all components except the *h*HSS1 primary antibody. The presence of *h*HSS1 was visualized by a reddish brown precipitate. The specificity of the *h*HSS1 polyclonal antibody was previously verified by Western blot analysis.

Anchorage-independent growth on soft agar {#Sec12}
-----------------------------------------

Medium containing U87 cells (8 × 10^4^) was mixed with a 0.33% low-melting agarose top suspension, which was then layered onto a 0.5% bottom agarose. Each assay was performed in triplicate. The plates were incubated at 37°C, 5% CO~2~ for 23 days; after that, nine fields of each plate were photographed and colonies were counted manually.

Intracranial xenograft in immunodeficient mice {#Sec13}
----------------------------------------------

Tumorigenicity in vivo was determined by intracranial injection of U87 glioma-derived cells in male Nu/Nu mice, age 6 weeks (Charles River Laboratories, Wilmington, MA, USA). Mice were quarantined for one week before initiation of the experimental procedure. Initially, mice were anesthetized with isoflurane (FORANE^®^). The skin was then cut using a scalpel and retracted for skull exposure. Skulls were punctured with a bone penetrator approximately 2 mm posterior to Bregma. After skull puncture, 10 μl of a 1 × 10^6^ cell suspension in PBS was injected with a 100 μl syringe containing a blunt end needle. The skin was replaced over the skull puncture and given two stitches. Mice subsequently recovered from the anesthesia within minutes and became mobile and active. No apparent ill effects were observed immediately after the cell injection. Three groups of mice were studied: U87 wild-type cells (N = 8), pcDNA3.1 (N = 5) and pcDNA3.1-*h*HSS1 (N = 5). All mice were properly treated in accordance with guidelines of the Institutional Animal Care and Use Committee (IACUC) at the BATTS Laboratories facility (Northridge, CA, USA).

Transcript expression profiling using microarray {#Sec14}
------------------------------------------------

*Affymetrix* GeneChip Human Gene 1.0 ST Array was used to obtain transcript expression profiles in wild type (non-transfected), mock stable-transfected (pcDNA3.1 empty vector) and *h*HSS1-stable-transfected (pcDNA3.1-*h*HSS1) U87 cells. Exponentially growing U87 cells at growth curve day 4 were harvested by trypsinization and the total RNA was isolated using the RNeasy minikit (Qiagen). Further RNA characterization and chip analysis was carried out at the Functional Genomics Core of the City of Hope (Duarte, CA, USA). Samples were evaluated in triplicate. Expression values were determined using dChip (July 9, 2009 build). For glioma tissue microarray, 100 primary gliomas from MD Anderson Hospital patients (GEO accession \#GSE4271) were arranged into Mesenchymal, Proneural, and Proliferative subclasses according to Phillips et al*.* \[[@CR8]\]. *h*HSS1 probeset expression (*Affymetrix* HG-U133 probeset, 224727_at) was then assessed in each group from MAS5-normalized data, and statistical differences between groups evaluated using one-tailed student's *t*-test after adjustment for variance.

Statistical analysis {#Sec15}
--------------------

For the proliferation assays, two-tailed Student's *t*-tests were performed to establish the statistical significance of differences between control cells and *h*HSS1-expressing cells. Differences among groups in the growth curve analysis were determined by two-way analysis of variance (ANOVA) with Tukey's test for pairwise post-hoc comparisons. Survival analysis was performed by the Kaplan--Meier test. Differences were considered statistically significant when *P* \< 0.05.

Results {#Sec16}
=======

Bioinformatics, cloning and sequencing of HSS1 and HSM1 {#Sec17}
-------------------------------------------------------

Using *Affymetrix* microarray analysis, approximately 900 highly and/or differentially expressed genes were identified from three subsets of murine HSC populations \[[@CR4]\]. Probe sets with significant expression in the HSC subsets of unknown gene products were subjected to BLAT analysis and examined for correspondence to novel *in silico* predicted genes. Predicted genes identified in this manner were then subjected to analysis for signal peptides using SignalP (<http://www.cbs.dtu.dk/services/SignalP/>) and the absence of a transmembrane domain, using TMHMM (<http://www.cbs.dtu.dk/services/TMHMM/>). In this manner, novel secretable proteins were identified. Gene expression corresponding to one probe (96320_at) found in all three stem cell subsets identified a downstream untranslated region of a predicted gene on mouse chromosome 7 (GenScan chr7_6.156) and on human chromosome 19 (GenScan NT_011109.821). The respective mouse and human gene predictions specified proteins with 86% identity to each other, neither of which was existent in the databank. These mouse and human genes predicted a signal peptide sequence, but no transmembrane domain, indicating that the sequences coded for secreted proteins. Both mouse and human genes were cloned from their respective mouse and human cDNA libraries via PCR using primers based upon the gene predictions. The clones were then sequenced and the predicted sequences were confirmed for both human and mouse. The secretable form of the gene was designated HSS1 (Fig. [1](#Fig1){ref-type="fig"}a). Additionally, GenBank entries indicated the presence of a splice variant of HSS1 containing a predicted membrane spanning domain. This isoform was also amplified by PCR from the cDNA libraries, confirmed for both human and mouse and was designated HSM1, the membrane associated splice variant of the gene (Fig. [1](#Fig1){ref-type="fig"}a). The mouse and human gene ID's are 69683 and 284361, respectively.Fig. 1**a** Protein sequence alignment for HSS1 and HSM1. Homology between the two splice variants in mouse and human are shown. Identical residues are indicated by *asterisks*. *Shaded* regions represent as follows: predicted signal peptide (*light grey*); predicted *N*-and *O*-glycosylation sites at the amino acid positions 182 and 198 (*black box*); predicted transmembrane domain for *h*HSM1 (*dark grey*, note it contains the ultimate intron--exon splice boundary which gives rise to the different forms of the gene): intron--exon junctions (*bold underlined*). **b** Intron--exon arrangement of *h*HSS1/HSM1. Each HSS1 and HSM1 contains seven exons. The last exon differs in both forms of the protein. *Small arrows* indicate PCR primer sites. TGA: stop codon. The two forms of the gene are encoded at *locus* 19q13.33

The full-length cDNA sequence of HSS1 consists of approximately 1.9 kb containing an open reading frame of 789 bp. This sequence was submitted to the NCBI database and assigned a GenBank accession number, namely AY761095. The genomic structure of HSS1, as well as HSM1, is composed of seven exons and six introns covering a minimum of 6.8 kb (Fig. [1](#Fig1){ref-type="fig"}b). The last exon is alternatively spliced resulting in either HSS1 or HSM1. The two forms of the gene are encoded at chromosome 19q13.33. Mouse and human HSS1/HSM1 share homology with ortholog genes in numerous species (Fig. [2](#Fig2){ref-type="fig"}a). The Beijing Genomics Institute Tree Families Database, for example, includes 45 different species to date as part of the family (TF314052**)**. Thus, the gene is evolutionarily conserved across species, phyla and kingdoms, including mammals, invertebrates and plants.Fig. 2**a** Phylogram of HSS1/HSM1 protein sequences. Alignment of HSS1/HSM1 protein sequences from 24 species using ClustalW2 (<http://www.ebi.ac.uk/Tools/clustalw2/index.html>). HSS1/HSM1 has identified orthologs in at least 45 species, of which 24 are shown. **b** and **c** Overlay of TOP7 fold with the HSS1/HSM1 predicted fold. **b** Alignment of TOP7 (*blue*) and HSS1/HSM1 (*green*) β-sheets (amino acids 54--159); **c** alignment of TOP7 (*red*) and HSS1/HSM1 (*green*) alpha-helices. The predicted probability of these two domains aligning by chance is *P* \< 0.05

HSS1 and HSM1 do not have sequence homology to known naturally occurring proteins {#Sec18}
---------------------------------------------------------------------------------

Since HSS1 was identified solely by bioinformatic analysis, and HSM1 was only one gene out of thousands of uncharacterized genes which had been sequenced in various EST or transcriptomic projects, no function could be attributed *a priori* to these genes. Towards the aim of elucidating a function for the proteins encoded by the HSS1 gene, we searched extensively for homology between HSS1/HSM1 and proteins with known functions. We also performed searches to ascertain whether HSS1/HSM1 contained domains common to a known protein and/or protein domain family. Using publicly available algorithms to identify protein domains and overall structure, we failed to find any homology with HSS1 or HSM1.

We then used a proprietary algorithm (Eidogen-Sertanty Inc., Oceanside, CA, USA) based on a 3-D, crystallographic protein database to align protein sequences of unknown structure. Interestingly, this search revealed homology to only one protein in the database. This protein was a non-natural, computationally designed protein, designated as TOP7 \[[@CR9]\]. From this analysis, we determined that a region common to HSS1 and HSM1 share structural homology with TOP7 at the 95% confidence level (Fig. [2](#Fig2){ref-type="fig"}b and c).

HSS1 is a novel secreted protein with a complex glycosylation pattern {#Sec19}
---------------------------------------------------------------------

Based on the primary sequence of HSS1, SignalP analysis showed that HSS1 has a predicted signal peptide, but according to TMHMM no transmembrane domain. To further confirm its potential secretory properties, *h*HSS1 was expressed in 293T cells as a construct containing a 6×His tag at its carboxyl terminal. Western blot analysis using an anti-6×His antibody confirmed that HSS1 is a secreted protein, as it was detected in the supernatant of transiently transfected 293T cells (Fig. [3](#Fig3){ref-type="fig"}a and b). Wild type 293T cells (Fig. [3](#Fig3){ref-type="fig"}b) and the cells transfected with empty vector (data not shown) yielded no protein via Western blot analysis.Fig. 3HSS1 is secreted and multi-glycosylated **a** Western blot analysis obtained from 293T cells transfected with the pTT3-*h*HSS1 construct in serum or serum-free medium. The protein was detected with anti-His-tag antibody. Samples were also digested with enzymes that selectively cleave glycosylated proteins. His Tag ladder (*lane 1*); denatured cell lysate (*lane 2*); cell lysate treated with different enzymes (*lanes 3*, *4* and *5*); denatured supernatant from cells grown in medium with serum (*lane 6*); supernatant with serum treated with different enzymes (*lanes 7*, *8* and *9*); denatured supernatant from cells grown in serum-free medium (*lane 10*); supernatant serum-free treated with different enzymes (*lanes 11*, *12* and *13*). **b** Western blot analysis from 293T cell. Serum free supernatant and cell lysate of 293T cells transiently transfected with *h*HSS1 (*lanes 2* and *4*, respectively). Serum free supernatant and cell lysate of wild type 293T cells (*lanes 3* and *5*, respectively)

We next wanted to confirm if HSS1 is glycosylated, as the predicted sequence presented two possible glycosylation sites at residues 182 and 198 (Fig. [1](#Fig1){ref-type="fig"}a) based on NetNGlyc and NetOGlyc analysis (<http://www.cbs.dtu.dk/services/>). Thus, cleavage of HSS1 by glycolytic enzymes was performed on the cell lysate and supernatants containing HSS1. The apparent molecular weight of unglycosylated HSS1 from analysis of the His tag ladder (Fig. [3](#Fig3){ref-type="fig"}a, lane 1) is approximately 30 kDa (Fig. [3](#Fig3){ref-type="fig"}a, lanes 2--5). The theoretical molecular weight of the mature (i.e. signal peptide cleaved) HSS1 is 24,171 Da. The majority of the protein in the cell lysate did not appear to be glycosylated as enzyme cleavage did not significantly change the apparent molecular weight. However, for HSS1 that is secreted and found in the supernatant, cleavage by various glycolytic enzymes incrementally decreased the apparent molecular weight of the protein (Fig. [3](#Fig3){ref-type="fig"}a, lanes 6--13), thus suggesting a complex glycosylation pattern.

*h*HSS1 has a growth inhibitory effect in glioma cells {#Sec20}
------------------------------------------------------

Following our initial characterization of the physical properties of HSS1, we next sought to determine a function for this novel protein. Since Mitelman Breakpoint Data revealed that *h*HSS1 is located in a chromosomal region known to have aberrations or deletions in a variety of cancers, including various gliomas \[[@CR10]\], we first investigated whether *h*HSS1 would affect the malignant proprieties of two well-studied human glioma-derived cell lines, namely A172 and U87. These glioblastoma cell lines were chosen for study because previously they were found to have deletions in a region corresponding to the gene *locus* of *h*HSS1 at 19q13.33 \[[@CR11]\]. However, because *h*HSS1 is expressed in normal brain tissues \[[@CR12]\], we checked whether these cell lines were expressing *h*HSS1 by using gene specific primers in a one-step RT-PCR reaction. We found that neither *h*HSS1 nor *h*HSM1 mRNA was detectable in these glioblastoma cell lines (Fig. [4](#Fig4){ref-type="fig"}a, lanes 1 and 4).Fig. 4Growth inhibitory effect of *h*HSS1 in glioma cells **a** RT-PCR analysis of the clones stably transfected with pcDNA3.1-*h*HSS1 or pcDNA3.1 empty vector selected for the experiments. A172 and U87 cell lines do not express detectable levels of *h*HSS1 (or *h*HSM1) (*lanes 1* and *4*, upper panel). PCR product from the stable clones expressing HSS1 (*lanes 2* and *5*) and mock-transfected cells (*lanes 3* and *6*); *C1*, positive control: 100 ng of pcDNA3.1-*h*HSS1 plasmid; *C2*, negative control: reaction reagent only. **b** A172 pcDNA3.1 and pcDNA3.1-*h*HSS1 transfected cells were seeded (8 × 10^4^ cells) and harvested after 7 days for cell counting by trypan blue exclusion. **c***h*HSS1 expression suppresses colony formation in A172. A172 pcDNA3.1 and pcDNA3.1-*h*HSS1 transfected cells were seeded (2 × 10^3^ cells), and after 23 days cells were stained with neutral red. **d** U87 pcDNA3.1 and pcDNA3.1-*h*HSS1 transfected cells were seeded (8 × 10^4^ cells) and harvested after 6 days for cell counting by trypan blue exclusion. **e** and **f***h*HSS1 expression decreases U87 cell aggregation in culture. **e** U87 cells (5 × 10^3^) were seeded in septuplicate in 96-well plates and incubated for 3 days, and then cell aggregates were photographed and counted. **f***h*HSS1-expressing cells presented a much flatter shape while the control cells typically grew in cell aggregates. All results are presented as grand mean ± SEM of two independent experiments. \* *P* \< 0.05, two-tailed independent Student's *t*-test

We then stably transfected A172 and U87 with a construct carrying *h*HSS1 cDNA (pcDNA3.1-*h*HSS1) or with the empty vector as control. The expression of *h*HSS1 following transfection was confirmed by using RT-PCR. The results showed that while *h*HSS1 mRNA was not detectable in non-transfected wild-type and mock-transfected cells, the selected pcDNA3.1-*h*HSS1-transfected clones stably expressed the *h*HSS1 mRNA (Fig. [4](#Fig4){ref-type="fig"}a, lanes 2 and 5).

During the selection of the stable clones, we observed that the growth of the pcDNA3.1-*h*HSS1 transfected cells was dramatically decreased relative to mock-transfected clones. Thus, cell counting and plating efficiency were performed to evaluate the relative proliferation of clones transfected with pcDNA3.1-*h*HSS1 or empty vector. The results obtained showed that A172- and U87-*h*HSS1-expressing glioblastoma cells decreased in cell number by 3-fold compared to mock-transfected cells (two-tailed independent Student's *t*-test*, P* \< 0.001) (Fig. [4](#Fig4){ref-type="fig"}b and d).

In addition to reduction in proliferation, expression of the *h*HSS1 gene in U87 cells induced morphological changes. We observed that cell aggregate formation in U87-mock-transfected cells were discernible (Fig. [4](#Fig4){ref-type="fig"}f), probably reflecting loss of contact inhibition in these cells. Cell aggregates can be viewed as clumps of cells that accumulate over an initial monolayer. This phenotype in U87 cells was also reported in a previous study of the Smac gene and its regulation of tumor cell viability \[[@CR13]\]. We next evaluated the number of cell aggregates formed between *h*HSS1-expressing cells and mock-transfected cells. The number of cell aggregates formed in U87 cells expressing *h*HSS1 was 5.9 times less relative to mock-transfected cells (two-tailed independent Student's *t*-test, *P* \< 0.001) (Fig. [4](#Fig4){ref-type="fig"}e). The number of cells counted in this experiment was 1.32 × 10^5^ (pcDNA3.1) and 3.35 × 10^4^ (pcDNA3.1-*h*HSS1) (two-tailed independent Student's *t*-test, *P* \< 0.02).

Since A172 cells do not display cell aggregate formation, we chose to assess the difference in plating efficiency for this cell line as an additional measure of proliferation and ability to grow at low density. We observed that the number of colonies formed by A172 cells expressing *h*HSS1 was dramatically decreased compared to the mock-transfected (Fig. [4](#Fig4){ref-type="fig"}c), indicating that *h*HSS1 expression efficiently reduced clonogenic cell survival.

Since we have verified the expression of *h*HSS1 in these cell lines only by mRNA levels, we then checked the expression of *h*HSS1 at the protein level by immunochemical analysis. Figure [5](#Fig5){ref-type="fig"} shows immunocytochemical analysis of U87 (Fig. [5](#Fig5){ref-type="fig"}a) and A172 (Fig. [5](#Fig5){ref-type="fig"}b) cell lines. No obvious staining was detectable in non-transfected and empty-vector transfected U87 cells (Fig. [5](#Fig5){ref-type="fig"}a.1--2). Immunoreactivity was evident throughout the cells overexpressing *h*HSS1, confirming that its transcript in U87 and A172 (Fig. [5](#Fig5){ref-type="fig"}a.3 and [5](#Fig5){ref-type="fig"}b.6, respectively) stable cells was translated into immmocytochemically detectable *h*HSS1 protein. Conversely, endogenous *h*HSS1 expression in some cells was detected in both non-transfected and empty-vector transfected A172 cells (Fig. [5](#Fig5){ref-type="fig"}b.4--5). However, the A172 *h*HSS1-transfected cells expressed higher levels of *h*HSS1 protein compared to the controls (Fig. [5](#Fig5){ref-type="fig"}b.6). Nuclear staining was observed in A172 cells, suggesting that *h*HSS1 may also localize inside the nucleus of these cells. Thus, *h*HSS1 could have both intra and extracellular properties as has been reported for FGFs and epidermal growth factor (EGF) proteins \[[@CR14]\]. Further experiments are needed to confirm this finding.Fig. 5Immunocytochemical localization of *h*HSS1 in cultured glioma-derived cells. **a**: *1*, U87 wild type cells; *2*, pcDNA3.1-transfected U87 cells; *3*, pcDNA3.1-*h*HSS1 transfected U87 cells. Pictures shown represent cells stained using anti-rabbit antibody against *h*HSS1. **b**: *4*, A172 wild type cells; *5*, pcDNA3.1-transfected A172 cells; *6*, pcDNA3.1-*h*HSS1 A172 transfected cells. *Red arrows* nuclear staining. Images are shown in the same magnification (200×)

To further examine the growth properties of the *h*HSS1-expressing cells, we constructed a growth curve for each cell line in order to determine whether *h*HSS1 overexpression increased the cell doubling time. The growth rate was significantly affected by *h*HSS1 overexpression in both A172 cells \[main effect of cell type, *F*(2, 135) = 98.61, *P* \< 0.001\] and U87 cells \[main effect of cell type, *F*(2, 135) = 51.36, *P* \< 0.001\]. A significant growth inhibition effect was observed after day 3 of experiment for both cell lines: A172 cells \[cell type X day interaction, *F*(16, 135) = 6.84, *P* \< 0.001\], U87 cells \[cell type X day interaction, *F*(16, 135) = 3.45, *P* \< 0.001\]. Moreover, the A172 wild-type and mock-transfected cells showed a doubling time of 27 and 30.5 h, respectively, whereas the A172 *h*HSS1-expressing cells showed a doubling time of 40 h (Fig. [6](#Fig6){ref-type="fig"}a). Similarly, while U87 wild-type and mock-transfected cells had a doubling time of 27.4 and 27.6 h, respectively, the U87 *h*HSS1-expressing cells had a doubling time of 32.1 h (Fig. [6](#Fig6){ref-type="fig"}b). Taken together, these results indicate that *h*HSS1, a novel secreted protein in a new protein class, has a growth-inhibitory effect in malignant glioma cells.Fig. 6*h*HSS1 expression inhibits A172 and U87 cell doubling. **a** and **b** A172 and U87 cells (wild-type, pcDNA3.1, pcDNA3.1-*h*HSS1) were cultured at nine different time points, harvested and counted by trypan blue exclusion. **a***h*HSS1 significantly inhibited the proliferation of A172 cells after 3 days in culture (\**P* \< 0.05, post-ANOVA pairwise Tukey test). **b***h*HSS1 significantly inhibited the proliferation of U87 cells after 3 days in culture (\**P* \< 0.05, post-ANOVA pairwise Tukey test). Results are shown as grand mean ± SEM of two independent experiments

*h*HSS1 suppresses the malignant phenotype of U87 cells in vitro and in vivo {#Sec21}
----------------------------------------------------------------------------

Changes in cell morphology are associated with malignant transformation in many epithelial tumor cells. Furthermore, malignantly transformed cells have the ability to grow in the absence of cell anchorage. To evaluate whether the morphological changes induced by *h*HSS1 expression (Fig. [4](#Fig4){ref-type="fig"}f) correlate with reduced malignancy in these cells, we compared the ability of U87 cells carrying either the empty vector or expressing *h*HSS1 to grow in an anchorage-independent manner. Results showed that empty vector control cells formed numerous colonies in soft agar compared to *h*HSS1-expressing cells (Fig. [7](#Fig7){ref-type="fig"}a). Moreover, the sizes of the colonies of empty vector control cells were markedly larger than those of cells expressing *h*HSS1 (Fig. [7](#Fig7){ref-type="fig"}b). These results suggest that stable expression of *h*HSS1 in U87 cells in which *h*HSS1 expression previously had been undetected produces a potentially less malignant phenotype by restoring the normal cell property of contact inhibition.Fig. 7*h*HSS1 suppresses anchorage-independent growth and tumorigenicity of U87 cells. **a** U87 cells (pcDNA3.1, pcDNA3.1-*h*HSS1) were seeded on top of soft agar in 10 cm plates and the number of colonies formed in soft agar were counted after 23 days of incubation. Results are expressed as grand mean ± SEM and are representative of two independent experiments. \* *P* \< 0.05, Student's *t*-test, pcDNA3.1-*h*HSS1 versus U87 wild-type or versus mock-transfected cells. **b** Micrograph of U87 colonies grown in soft agar: pcDNA3.1: mock-transfected cells, pcDNA3.1-*h*HSS1: cells stably expressing *h*HSS1. **c** Kaplan--Meier analysis of nude mice intracranially injected with 1 × 10^6^ U87 cells expressing *h*HSS1 (N = 5), U87 wild-type (N = 8) or mock-transfected cells (N = 5) (Mantel test, *P* \< 0.001,). Survival and tumor growth were monitored daily

We also evaluated the ability of transplanted U87 cells to affect survival in immunocompromised mice (A172 cells were not studied as these cells are not tumorigenic in mice). Mice implanted with U87 *h*HSS1-expressing cells survived significantly longer, as compared to those implanted with U87 wild-type cells or cell carrying the empty vector (78 days vs 34 and 30 days for mock-transfected and wild-type cells, respectively; *P* \< 0.0001; log-rank). This result suggests that *h*HSS1 decreases the malignancy of U87 cells in vivo (Fig. [7](#Fig7){ref-type="fig"}c).

*h*HSS1 alters gene expression profile in stably-transfected U87 cells {#Sec22}
----------------------------------------------------------------------

The observed growth inhibitory effect of *h*HSS1, as well as its suppression of tumorigenicity in vitro and in vivo*,* raises the question of the molecular basis for such phenotypical changes. Comparative gene expression profiling using *Affymetrix* GeneChip Human Gene 1.0 ST of wild-type (non-transfected), mock-stable-transfected (pcDNA3.1 empty vector) and *h*HSS1-stable-transfected (pcDNA3.1-*h*HSS1) U87 cells allowed us to address this question.

Expression profiles of U87, mock and *h*HSS1-transfected stable cell lines were obtained and compared by two-tailed paired Student's *t*-test. Differential expression due to the presence of *h*HSS1 was defined as being statistically significant (*P* \< 0.05) for the *h*HSS1-transfected cells compared to both U87 wild-type and the mock transfected controls with the added criterion that difference in gene expression between U87 wild-type and mock transfected cells must not be statistically significant (*P* \> 0.05). After these stringent criteria were met, 491 genes were found to have altered expression levels of at least two-fold. A volcano plot is shown in Fig. [8](#Fig8){ref-type="fig"}. Among these genes were *h*HSS1 itself which exhibited more than 10-fold increase in expression in the *h*HSS1 stable-transfected cells compared to mock stable-transfected (*P* = 0.00013) and U87 wild-type cells (*P* = 0.00015). The expression levels of *h*HSS1 between U87 wild-type and the mock stable-transfected cells was not statistically significant (*P* = 0.39). These findings for *h*HSS1 in the expression profile analysis are indicative of the integrity of the analysis. Overall, 166 probe-set defined genes were up-regulated and 325 were down-regulated by at least two-fold demonstrating that *h*HSS1 expression alters the gene expression profile of U87 cells. Table [1](#Tab1){ref-type="table"} displays 8 genes up or down-regulated by *h*HSS1.Fig. 8Volcano plot for 491 differentially *h*HSS1-regulated genes in U87 stable transfected cells. Values outside −1 and +1 fold change and values above negative log *P*-value 1.3 (*P* = 0.05) were considered statistically significant down- (*left*) and up-regulated (*right*)Table 1Select genes either up or down-regulated in U87 cells stably expressing *h*HSS1 as indicated by microarray analysisGene*h*HSS1 vs pcDNA3.1\
Fold change*P*-valueU87-wild type vs pcDNA3.1\
Fold change*h*HSS1 vs U87-wild type*h*HSS1 vs pcDNA3.1U87-wild type vs pcDNA3.1*hHSS1\**+11.70.000150.000130.391.0*APLN*−140.00040.000030.141.0*SIK1*+2.30.0030.003250.13−1.1*ADAMTS1*+2.90.0030.002030.231.0*BRCA1*−2.70.00020.000320.121.0*BRCA2*−2.60.00070.000510.07−1.1*CDK2*−2.20.00080.000640.241.0*CDK6*−3.10.0010.000500.06−1.1*ASF1B*−4.50.000050.000470.461.0*P*-values were determined by two-tailed paired Student's *t*-test. \* Official gene symbol for *h*HSS1 is *C19orf63*

*h*HSS1 expression in glioma-derived tissues {#Sec23}
--------------------------------------------

Next, we examined the expression of *h*HSS1 by transcript profiling in brain cancer and normal brain. The analysis of the Brain Cancer Tissue qPCR Array I showed expression in normal and all tumor grades with a decreased expression of *h*HSS1 in WHO grade IV (glioblastoma multiform) (Fig. [9](#Fig9){ref-type="fig"}a). Further, using the Human Brain Tissue qPCR Panel I *h*HSS1 expression was found at low levels in normal tissues from various brain regions, with highest levels in pituitary tissue (Fig. [9](#Fig9){ref-type="fig"}b). Overall, the mRNA level of *h*HSS1 relative to the reference genes (GAPDH and β-actin) was very low in both surveys.Fig. 9**a** Expression profiles of *h*HSS1 in brain cancer according to WHO classification. TissueScan Brain Cancer Tissue qRT-PCR Array I consisting of 48 human brain tissues was used to determine transcript levels of *h*HSS1. Data were normalized to β-actin levels. Error bars displays the SEM. **b** Expression profiles of *h*HSS1 in human brain tissues (Human Brain Tissue qPCR Panel I). Data were normalized to GAPDH levels

We also evaluated the distribution of *h*HSS1 in low-grade diffuse astrocytoma (WHO grade II) and high-grade astrocytoma (glioblastoma multiforme, WHO grade IV) using immunohistochemical analysis (Fig. [10](#Fig10){ref-type="fig"}). Overall, no obvious detection of *h*HSS1 was found in normal brain tissue (Fig. [10](#Fig10){ref-type="fig"}a and d). High expression levels of *h*HSS1 were found in two out of four grade IV astrocytomas (Fig. [10](#Fig10){ref-type="fig"}c and f). On the contrary, all four grade II astrocytomas showed low expression of *h*HSS1 (Fig. [10](#Fig10){ref-type="fig"}b and e). A minimum perivascular staining was also observed, mostly in tumor areas. Although the expression of *h*HSS1 was predominantly detected in cytoplasm, nuclear stain was seen focally, as observed in A172 cells. Moreover, *h*HSS1 was detected in some but not all tumor cells. It is important to mention that both sets of primers used in the qRT-PCR and the antibody used to detect *h*HSS1 do not discriminate between the secreted and membrane bound form of the protein (*h*HSM1).Fig. 10Immunohistochemical analysis of *h*HSS1 in representative cases of glioma. **a**, **d** No obvious immunoreactivity was detectable in normal brain tissues). **b**, **e***h*HSS1 immunoreactivity was low in low-grade diffuse astrocytoma (WHO grade II). **c**, **f** low and high expression of *h*HSS1 in high-grade astrocytoma (glioblastoma multiforme, WHO grade IV). Sections were stained using anti-rabbit antibody against *h*HSS1. Images are shown in the same magnification (200×)

*h*HSS1 expression in glioma molecular subclasses {#Sec24}
-------------------------------------------------

Since *h*HSS1 expression was only detectable on a subset of high-grade gliomas, we considered whether *h*HSS1 was differentially up-regulated on functionally distinct molecular subclasses of gliomas. Such subclasses are distinguishable by microarray, and include mesenchymal (MES), proneural (PN), and proliferative (Prolif) subclasses. In light of the *h*HSS1 transfection data, which suggested that *h*HSS1 expression may alter anchorage-dependent growth and/or cell morphology in vitro, it was particularly intriguing to consider whether *h*HSS1 was differentially expressed on MES subclass gliomas, which up-regulate genes involved in cell motility and invasiveness. Indeed, relative up-regulation of *h*HSS1 expression uniquely characterized MES subclass gliomas, which expressed significantly more *h*HSS1 on microarray than either PN or Prolif subclass gliomas (Fig. [11](#Fig11){ref-type="fig"}). Since both MES and Prolif subclasses include de novo high-grade gliomas, whereas the PN subclass is largely devoid of these tumors, this finding further validates the notion that high *h*HSS1 expression is confined to a subset of high-grade gliomas generally, and to the MES subclass in particular.Fig. 11Expression of *h*HSS1 by glioma molecular subclasses. Expression data from 100 primary gliomas from MD Anderson Hospital patients (GEO accession \#GSE4271) were arranged into Mesenchymal (MES; n = 35), Proneural (PN; n = 37), and Proliferative (Prolif; n = 28) groups according to Phillips et al*.* \[[@CR8]\]. *h*HSS1 probeset (*Affymetrix* HG-U133, 224727_at) expression was assessed in each group from MAS5-normalized data. Statistical differences between groups was evaluated using one-tailed *t*-test after adjustment for variance, with *P* values as shown. Mean expression ± SEM was as follows: *MES*, 3057 ± 211; *PN*, 2408 ± 125; *Prolif*, 2345 ± 244

Discussion {#Sec25}
==========

In this study, we have identified and characterized HSS1, a novel secreted factor, and its membrane-bound splice variant, HSM1. Moreover, we report that HSS1 and HSM1 are two members of a novel protein class, and that these novel proteins have growth inhibitory properties in two glioblastoma cell lines.

The fact that HSS1 and HSM1 are evolutionarily conserved across numerous species, phyla and even kingdoms, including mammals, invertebrates and plants, suggests that these proteins are of fundamental significance in biology. Yet neither human nor murine HSS1/HSM1 show homology to known, naturally occurring proteins, nor do they contain known functional domains. After using a 3-D crystallographic protein database to align protein sequences of unknown structure, it was found that a region common to HSS1/HSM1 shares structural homology with TOP-7, which is a non-natural, idealized protein designed *in silico* for stability at extreme temperature and pH conditions \[[@CR9]\]. It is, therefore, intriguing to speculate whether HSS1/HSM1 might also exhibit such stability.

High-throughput gene expression analysis of diverse mouse and human tissue samples has shown that HSS1/HSM1 is widely expressed in body tissues including brain \[[@CR12]\]. We discovered HSS1/HSM1 by its differential expression pattern in highly purified HSCs, thus suggesting a possible role for this secreted factor in stem cell regulation. Interestingly, in a previous report *h*HSS1/HSM1 was shown to be a component of the transcriptome involved in the signaling networks that control human embryonic stem cell growth and differentiation \[[@CR15]\]. Numerous recent reports have revealed a connection between stem cell biology and tumor biology \[[@CR16]\]; thus it is possible that HSS1 may have a role in both areas.

Gene expression data from the CGAP database does indicate that HSS1 may be involved in numerous cancers, such as brain, colon, eye, liver, lymph node, mammary gland, ovary, prostate and skin \[[@CR17], [@CR18]\]. Moreover, Mitelman breakpoint data for the gene corresponding to HSS1 indicate that its gene *locus* is a "hot spot" for chromosomal aberrations implicated in a variety of human cancers \[[@CR10]\], thereby suggesting a broad role for *h*HSS1 in cancer.

Upon the discovery of HSS1, only two facts guided the search for a function for this novel protein. First, HSS1 was highly expressed in HSCs and its human genetic *locus* was at 19q13.33. Since chromosome 19q also harbors at least one gene important for normal glial development and growth regulation as well as for the development of diffuse gliomas \[[@CR5], [@CR6], [@CR19]\], we chose to first investigate a possible role for *h*HSS1 in glioma. Another suggestive link between *h*HSS1 and glioma was that the common region for frequent deletions in glioma involves the 19q13.2-13.4 position \[[@CR5]\]. This position is situated distal to the *D19S178* marker and proximal to the *D19S180* marker \[[@CR5], [@CR20]\], a region which includes the *h*HSS1 gene (Fig. [12](#Fig12){ref-type="fig"}).Fig. 12Mapped position of the putative glioma tumor suppressor at chromosome 19q region **a** Chromosome 19 (q13.31--q13.43), region of the putative glioma tumor suppressor suggested by von Deimling et al*.* \[[@CR20]\], between the markers *D19S178* and *D19S180* (*red rectangle*). This region includes the *h*HSS1 gene (*C19orf63*). **b** Chromosome 19 (q13.32--q13.33), region of the putative glioma tumor suppressor gene narrowed by Rubio et al. \[[@CR5]\] (*smaller red rectangle*). This region is situated between the *lociAPOC2* and *HRC*, which excludes the *h*HSS1 gene. **c** Chromosome 19q13.33, *red bar* represent the genome location of *h*HSS1. The UCSC database was used as reference (<http://genome.ucsc.edu/cgi-bin/hgGateway>)

Although chromosome 19q may harbor a potential pan-glioma tumor suppressor gene, to date, the glioma suppressor genes in this chromosome region remain elusive. Thus, we investigated the effect of ectopic expression of *h*HSS1 on the malignant properties of glioma-derived cells. The results showed that *h*HSS1 expression dramatically decreased the growth rate of U87 and A172 glioma-derived cells. In addition, stable expression of *h*HSS1 in A172 cells strongly inhibited their capacity to grow in low density compared with control cells, which might express endogenous *h*HSS1 at low levels. The ability to reduce their growth in low density was also observed for U87 cells stably transfected with *h*HSS1 (data not shown).

It was also striking that U87 cells expressing *h*HSS1 formed 5.9 times fewer cell aggregates compared to mock-transfected cells. The results also indicate that the expression of *h*HSS1 may promote growth suppression in U87 cells involving a decrease in growth rate following a decrease in the cell doubling-time. Further experiments are needed to clarify the mechanism by which *h*HSS1 suppresses the growth of U87 and A172 cells.

The expression of *h*HSS1 also significantly attenuated the colony-forming ability of U87 cells in soft agar matrix, further indicating a possible involvement of *h*HSS1 in restoration of contact inhibition. In addition, mice injected with U87 cells expressing *h*HSS1 showed on average greater than 2-fold extension of their life span, indicating that *h*HSS1 affected the malignant phenotype of glioma-derived cells.

Comparative expression profiling results using *Affymetrix* gene chip demonstrated that the stable expression of *h*HSS1 in U87 cells significantly altered its gene expression profile. A substantial number of genes were observed to be either up- or down-regulated by at least two-fold. Presumably genes among this population contribute to the phenotype observed for the *h*HSS1 stable-transfected cells. Of immediate note and worth mention are the following observations. Apelin was seen as one of the most down-regulated genes in *h*HSS1-overexpressing cells with an approximate 14-fold decrease in expression. Apelin expression has been observed to be highly up-regulated in the microvasculature in brain tumors. In particular, apelin has been shown to be needed for intersomitic vessel angiogenesis and the promotion of angiogenesis in brain tumors \[[@CR21]\]. The fact that the expression of apelin is highly down-regulated in the *h*HSS1-overexpressing cells is consistent with the observed in vivo results where tumor growth was greatly suppressed, thereby leading to a significant increase in survival. It is of further interest that SIK1 (salt inducible kinase 1) gene was among the highly up-regulated genes. This finding is intriguing in that SIK1 has been shown to be a regulator of anoikis and a suppressor of metastasis \[[@CR22]\]. Metastatic tumors generally will avoid anoikis despite loss of adherence. In the case of *h*HSS1 stable-transfected cells, the increase in SIK1 would presumably correspond to an increase in anoikis and decrease in metastasis, thus suppressing tumor growth and spread. The ADAMTS1 gene was also up-regulated in *h*HSS1 stable-transfected cells. This metalloproteinase has been found to suppress tumorigenicity and metastasis in model systems \[[@CR23], [@CR24]\]. Further changes in gene expression to note in *h*HSS1-overexpressing cells include down-regulation of both BRCA1 and BRCA2 genes, a number of cell cycle associated genes (e.g. CDK2, CDK6), tubulins and the histone chaperone gene ASF1B along with a number of other histone genes. Validation of these and other genes of interest are underway.

In tumor tissues, the overall expression levels of *h*HSS1 were low and variable and the analysis of more tumor samples are needed to form a definite conclusion. However it is interesting to note that *h*HSS1 expression was observed minimally in all 4 low-grade diffuse astrocytomas (WHO grade II) analyzed, while half of the high-grade astrocytomas (glioblastoma multiforme, WHO grade IV) exhibited increased expression. This finding is in agreement with previous reports suggesting a correlation between low-grade gliomas and deletion of 19q13 region \[[@CR25]\]; this deletion is less common in high-grade gliomas. Moreover, the notion that only a subset of high-grade gliomas over-expresses *h*HSS1 was further supported by microarray data, which indicated that MES subclass gliomas exclusively up-regulated *h*HSS1. This finding is intriguing in light of transfectant data that suggested stable expression of *h*HSS1 alters glioma anchorage-independent growth and morphology, thus implicating a functional role of *h*HSS1 in glioma growth and/or invasiveness. Further studies are required to test this hypothesis and to clarify if the high-expression of *h*HSS1 in high-grade gliomas are due to (a) mutations in *h*HSS1 itself; (b) mutations in downstream effectors of *h*HSS1; (c) interruption of pathways not related to *h*HSS1; and (d) detection of the splice variant of *h*HSS1 (*h*HSM1).

Previous studies have suggested a few candidate glioma tumor suppressor genes in a 150-kilobase region that maps to 19q13.33 \[[@CR5], [@CR6]\]. It has been reported that alterations in *GLTSCR1* are associated with the development and progression of oligodendroglioma \[[@CR26]\]. Furthermore, *p190RhoGAP,* a gene located at 19q13.3, regulates critical components of PDGF oncogenesis and can act as a tumor suppressor in PDGF-induced gliomas by down regulation of Rho activity \[[@CR27]\]. Our present studies suggest that *h*HSS1 is another factor located at 19q13.33 that is involved in suppression of glioma growth.

In conclusion, our data show that (i) *h*HSS1 is a novel, previously uncharacterized, secreted factor located within a previously defined candidate tumor suppressor gene region at 19q13.33 and (ii) *h*HSS1 is implicated in the growth inhibition and restoration of the normal contact inhibition properties of glioma-derived cells. Thus, the discovery of the novel secreted protein, *h*HSS1, and the elucidation of its functional role in the inhibition of glioma could provide the opportunity to develop novel treatment strategies for malignant gliomas.
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